Dan Stanton, of BioPharma-Reporter.com, describes the move made by the European Medicines Agency (EMA) at the beginning of the Summer of 2013 to approve two more biosimilars. This approval of these biosimilars pushes the total available in Europe to fourteen. Deepa Prasad, a Coherus spokesperson commented on the increased number of biosimilars by saying, “Companies now can clearly see the commercial viability of biosimilar products as regulatory risk is perceived as less.” Do you think the increasing number of biosimilars approved in Europe will impact FDA actions?  To read the full article, click here.